Company Overview of Genomatica, Inc.
Genomatica, Inc. delivers manufacturing processes to produce intermediate and basic chemicals from renewable feedstocks. The company’s proprietary biotechnology platform allows the company to create fermentation-based manufacturing processes and to engineer the enabling microorganisms that drive the conversion of renewable feedstocks into intermediate and basic chemicals. It is developing a pipeline of manufacturing processes for the production of 20 intermediate and basic chemicals, including butanediol and butadiene. The company intends to offer its chemical products to large consumer products or chemical companies. Genomatica, Inc. was founded in 1998 and is headquartered in San Diego, Ca...
4757 Nexus Center Drive
San Diego, CA 92121
Founded in 1998
Key Executives for Genomatica, Inc.
Co-Founder and Chairman of Scientific Advisory Board
Executive Vice President and Chief Financial Officer
Vice President of Operations
Compensation as of Fiscal Year 2014.
Genomatica, Inc. Key Developments
Genomatica, Inc. Presents at World Congress on Industrial Biotechnology, May-12-2014
May 9 14
Genomatica, Inc. Presents at World Congress on Industrial Biotechnology, May-12-2014 . Venue: Philadelphia, Pennsylvania, United States.
Genomatica Appoints Kaspar Evertz as Executive Vice President, Commercial
May 6 14
Genomatica announced the appointment of Kaspar Evertz, Ph.D., as Executive Vice President, Commercial. Evertz will lead the company’s business development, licensing, and technology transfer teams with a focus on licensing its process technologies, and the delivery and execution of those licenses. He also will be responsible for securing strategic partners to support the development of additional commercial processes through sponsored development programs. Evertz brings 24 years of major chemical industry experience, particularly in licensing. Evertz joins Genomatica from Ferrostaal AG, where he was executive vice president and managing director of industrial projects. Genomatica’s current Chief Business Development Officer, William H. Baum, will transition to a part-time role, where he will focus on special projects and continue his role on the company’s Board of Directors, where he has been a member since 2006.
Braskem Signs Joint Development Agreement with Genomatica for Bio-Based Butadiene
Dec 11 13
Braskem and Genomatica announced an agreement for the joint development of commercial process technology to make bio-based butadiene from renewable feedstocks. Under the agreement, Braskem anticipates providing significant funding of Genomatica's development work over several years; will allocate significant Braskem R&D resources; and fund the construction and operation of pilot and demonstration-scale butadiene production plants using the process. In return, Braskem will receive certain exclusive license rights to use the resulting process technology in the Americas. Genomatica will also receive fees and royalties for each licensed commercial plant. The new agreement adds significantly to Genomatica's butadiene program, which now includes investments of over $100 million anticipated under current agreements. Program milestones already include the successful production of pounds of butadiene in 2011, and funding from Versalis for Genomatica's development efforts announced in April 2013. The combined strength of current and future program partners will facilitate aggressive pursuit and delivery of commercial-grade process technologies for licensing to and use by the global chemical industry, using a range of feedstocks. The agreements with Braskem and Versalis provide a commercialization path in all major butadiene-producing and consuming regions of the world.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|